LUMO | Lumos Pharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.70 - 3.91
52 Week Range	1.3700 - 4.55
Beta	-1.44
Implied Volatility	N/A
IV Rank	74.11%
Day's Volume	140,954
Average Volume	76,288
Shares Outstanding	8,124,040
Market Cap	30,871,352
Sector	Healthcare
Industry	Biotechnology
IPO Date	2011-11-11

Valuation
Profitability
Growth
Health
P/E Ratio	-0.86
Forward P/E Ratio	N/A
EPS	-4.42
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	33
Country	USA
Website	LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

LUMO's peers: ACXP, APRE, CKPT, CLRB, CMMB, FBIO, KTRA, PRDS, STTK, ELYM, CSBR, IPSC, SILO, PTIXW, RZLT, ANEB, ZIVO, THRX, ERAS, FBRX, AMTI, MRKR, XCUR, PLUR, MAIA, IMNN, KA, TOVX

*Chart delayed

Analyzing fundamentals for LUMO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see LUMO Fundamentals page.

Watching at LUMO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LUMO Technicals page.